Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of (64)Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates

PURPOSE: We recently developed a chelating platform based on the macrocycle 1,4,7-triazacyclononane with up to three five-membered azaheterocyclic arms for the preparation of (68)Ga- and (64)Cu-based radiopharmaceuticals. Based on this platform, the chelator scaffold NOTI-TVA with three additional carboxylic acid groups for bioconjugation was synthesized and characterized. The primary aims of this proof-of-concept study were (1) to evaluate if trimeric radiotracers on the basis of the NOTI-TVA 6 scaffold can be developed, (2) to determine if the additional substituents for bioconjugation at the non-coordinating NH atoms of the imidazole residues of the building block NOTI influence the metal binding properties, and (3) what influence multiple targeting vectors have on the biological performance of the radiotracer. The cyclic RGDfK peptide that specifically binds to the α(v)ß(3) integrin receptor was selected as the biological model system. PROCEDURES: Two different synthetic routes for the preparation of NOTI-TVA 6 were explored. Three c(RGDfK) peptide residues were conjugated to the NOTI-TVA 6 building block by standard peptide chemistry providing the trimeric bioconjugate NOTI-TVA-c(RGDfK)(3) 9. Labeling of 9 with [(64)Cu]CuCl(2) was performed manually at pH 8.2 at ambient temperature. Binding affinities of Cu-8, the Cu(2+) complex of the previously described monomer NODIA-Me-c(RGDfK) 8, and the trimer Cu-9 to integrin α(v)ß(3) were determined in competitive cell binding experiments in the U-87MG cell line. The pharmacokinetics of both (64)Cu-labeled conjugates [(64)Cu]Cu-8 and [(64)Cu]Cu-9 were determined by small-animal PET imaging and ex vivo biodistribution studies in mice bearing U-87MG xenografts. RESULTS: Depending on the synthetic route, NOTI-TVA 6 was obtained with an overall yield up to 58 %. The bioconjugate 9 was prepared in 41 % yield. Both conjugates [(64)Cu]Cu-8 and [(64)Cu]Cu-9 were radiolabeled quantitatively at ambient temperature in high molar activities of A(m) ~ 20 MBq nmol(−1) in less than 5 min. Competitive inhibitory constants IC(50) of c(RDGfK) 7, Cu-8, and Cu-9 were determined to be 159.5 ± 1.3 nM, 256.1 ± 2.1 nM, and 99.5 ± 1.1 nM, respectively. In small-animal experiments, both radiotracers specifically delineated α(v)ß(3) integrin-positive U-87MG tumors with low uptake in non-target organs and rapid blood clearance. The trimer [(64)Cu]Cu-9 showed a ~ 2.5-fold higher tumor uptake compared with the monomer [(64)Cu]Cu-8. CONCLUSIONS: Functionalization of NOTI at the non-coordinating NH atoms of the imidazole residues for bioconjugation was straightforward and allowed the preparation of a homotrimeric RGD conjugate. After optimization of the synthesis, required building blocks to make NOTI-TVA 6 are now available on multi-gram scale. Modifications at the imidazole groups had no measurable impact on metal binding properties in vitro and in vivo suggesting that the NOTI scaffold is a promising candidate for the development of (64)Cu-labeled multimeric/multifunctional radiotracers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11307-020-01530-8) contains supplementary material, which is available to authorized users.